ロード中...
Loss of Scribble confers cisplatin resistance during NSCLC chemotherapy via Nox2/ROS and Nrf2/PD-L1 signaling
BACKGROUND: Cisplatin resistance remains a major clinical obstacle to the successful treatment of non-small cell lung cancer (NSCLC). Scribble contributes to ROS-induced inflammation and cisplatin-elevated toxic reactive oxygen species (ROS) promotes cell death. However, it is unknown whether and ho...
保存先:
| 出版年: | EBioMedicine |
|---|---|
| 主要な著者: | , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Elsevier
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6796531/ https://ncbi.nlm.nih.gov/pubmed/31495720 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2019.08.057 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|